Suppr超能文献

诱变与致癌作用机制概述。

An overview of the mechanisms of mutagenesis and carcinogenesis.

作者信息

Sarasin Alain

机构信息

Laboratory of Genetic Instability and Cancer, Gustave Roussy Institute, UPR2169-CNRS, 39 rue Camille Desmoulins, 94805 Villejuif, France.

出版信息

Mutat Res. 2003 Nov;544(2-3):99-106. doi: 10.1016/j.mrrev.2003.06.024.

Abstract

Cancer is a genetic disease due to the accumulation of numerous mutations rendering the tumour cell insensitive to control by the local cellular environment and by the whole organism. Analysis of the frequency of appearance of human cancer as a function of age shows that between four and seven mutations in key genes are usually necessary to produce most human cancers. Interesting debates in the literature are concerned with the idea that normal mutation rates followed by selective advantage of mutated clones are enough to produce the numerous mutations found in human cancers. Alternatively, the mutator phenotype hypothesis is based on the idea that the normal mutation rates are insufficient to account for the multiple mutations found in tumours. It is, however, difficult not only to know this exact mutation frequency in cells but also to know the total number of cell divisions giving rise to a cancer. Therefore, during at least one step in the carcinogenic process, a mutator phenotype in target cells may occur due to mutations controlling the fidelity of DNA replication or DNA repair, the apoptosis pathways or the cell cycle checkpoint regulations. Among the multiple mutations found in human cancers such as gene amplification, chromosome alterations and translocations, point mutations are very important and the molecular mechanisms of their production are well documented. I will describe in detail the various mechanisms that a cell can use to produce point mutations due to lower fidelity in the DNA polymerisation step or to inefficient repair pathways. The presence of multiple mutations in human cancer is interesting not only in terms of understanding the carcinogenesis process in humans but also in eventually promoting strategies to decrease the efficiency of this process and to increase cancer therapy regimen.

摘要

癌症是一种遗传性疾病,由于众多突变的积累,使肿瘤细胞对局部细胞环境和整个机体的调控不敏感。分析人类癌症发病率随年龄的变化情况表明,产生大多数人类癌症通常需要关键基因发生4到7次突变。文献中有趣的争论涉及这样一种观点,即正常的突变率加上突变克隆的选择性优势足以产生人类癌症中发现的众多突变。另外,突变体表型假说基于这样一种观点,即正常的突变率不足以解释肿瘤中发现的多种突变。然而,不仅很难知道细胞中确切的突变频率,而且也很难知道导致癌症的细胞分裂总数。因此,在致癌过程的至少一个阶段,由于控制DNA复制保真度、DNA修复、凋亡途径或细胞周期检查点调控的基因突变,靶细胞中可能会出现突变体表型。在人类癌症中发现的多种突变,如基因扩增、染色体改变和易位中,点突变非常重要,其产生的分子机制已有充分记载。我将详细描述细胞由于DNA聚合步骤中较低的保真度或低效的修复途径而产生点突变的各种机制。人类癌症中存在多种突变不仅在理解人类致癌过程方面很有趣,而且最终在促进降低这一过程效率和增加癌症治疗方案的策略方面也很有趣。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验